Understanding the Fundamentals of Target Selection and Challenges Associated with Engineering TCR/TCRm Affinity/Specificity in pHLA Targeting
- Exploring untapped opportunities in both canonical and “dark antigen” spaces to offer substantial new opportunities for cancer patients
- Comparing pHLA epitope targeting with antibody-based surface antigen targeting to assess therapeutic quality and patient benefit
- Enhancing engineering precision in TCR/TCRm affinity and specificity to safely and effectively target pHLA with maximal clinical impact